Inventor · disambiguated record
Roger Beerli
Also filed as: BEERLI ROGER · BEERLI ROGER R · BEERLI ROGER RENZO
21 granted patents·13 pending applications·121 citations·filing 2000–2022
94Inventor score
Files withNBE THERAPEUTICS AG20SCRIPPS RESEARCH INST4CYTOS BIOTECHNOLOGY AG3SOTIO BIOTECH A S3BACHMANN MARTIN F1
Top patents by PatentIndex Score
34 records- 0197US11364301B2Method of producing an immunoligand/payload conjugateNBE THERAPEUTICS AG·Filed 2020·Granted Jun 21, 2022·6 cites·20 claims
- 0296US11242388B2ROR1 antibody compositions and related methodsNBE THERAPEUTICS AG·Filed 2020·Granted Feb 8, 2022·8 cites·12 claims
- 0396US10864277B2Method of producing an immunoligand/payload conjugateNBE THERAPEUTICS AG·Filed 2017·Granted Dec 15, 2020·13 cites·36 claims
- 0494US10960083B2Binding protein drug conjugates comprising anthracycline derivativesNBE THERAPEUTICS AG·Filed 2019·Granted Mar 30, 2021·6 cites·13 claims
- 0593US10618959B2ROR1 antibody compositions and related methodsNBE THERAPEUTICS AG·Filed 2018·Granted Apr 14, 2020·11 cites·26 claims
- 0693US9872923B2Method of producing an immunoligand/payload conjugateNBE THERAPEUTICS AG·Filed 2014·Granted Jan 23, 2018·19 cites·14 claims
- 0789US10758556B2Anthracycline-based antibody drug conjugates having high in vivo tolerabilityNBE THERAPEUTICS AG·Filed 2019·Granted Sep 1, 2020·8 cites·31 claims
- 0887US8344111B2Human monoclonal nicotine specific antibodiesCYTOS BIOTECHNOLOGY AG·Filed 2008·Granted Jan 1, 2013·8 cites·20 claims
- 0986US7011972B2Fusion polypeptide comprising two ligand binding domainsSCRIPPS RESEARCH INST·Filed 2001·Granted Mar 14, 2006·15 cites·33 claims
- 1085US10517959B2Binding protein drug conjugates comprising anthracycline derivativesNBE THERAPEUTICS AG·Filed 2018·Granted Dec 31, 2019·3 cites·8 claims
- 1185US10188745B2Binding protein drug conjugates comprising anthracycline derivativesNBE THERAPEUTICS AG·Filed 2015·Granted Jan 29, 2019·4 cites·28 claims
- 1282US11447546B2Human antibodies binding to ROR2NBE THERAPEUTICS AG·Filed 2018·Granted Sep 20, 2022·2 cites·5 claims
- 1381US7329728B1Ligand activated transcriptional regulator proteinsSCRIPPS RESEARCH INST·Filed 2000·Granted Feb 12, 2008·15 cites·61 claims
- 1480US11986535B2Method of producing an immunoligand/payload conjugateNBE THERAPEUTICS AG·Filed 2022·Granted May 21, 2024·0 cites·23 claims
- 1574US11833120B2Binding protein drug conjugates comprising anthracycline derivativesNBE THERAPEUTICS AG·Filed 2021·Granted Dec 5, 2023·0 cites·18 claims
- 1673US8460670B2Fully human influenza M2 specific antibodiesBACHMANN MARTIN F·Filed 2009·Granted Jun 11, 2013·1 cites·21 claims
- 1770US2022153839A1Ror1 antibody compositions and related methodsNBE THERAPEUTICS AG·Filed 2021·Application pending·0 cites
- 1866US12275789B2Human antibodies binding to ROR2NBE THERAPEUTICS AG·Filed 2022·Granted Apr 15, 2025·0 cites·9 claims
- 1965US7442784B2Ligand activated transcriptional regulator proteinsSCRIPPS RESEARCH INST·Filed 2003·Granted Oct 28, 2008·2 cites·34 claims
- 2059US2008318839A1Ligand activated transcriptional regulator proteinsBARBAS III CARLOS F·Filed 2008·Application pending·0 cites
- 2158US12121527B2Anthracycline-based antibody drug conjugates having high in vivo tolerabilityNBE THERAPEUTICS AG·Filed 2020·Granted Oct 22, 2024·0 cites·19 claims
- 2255US7741110B2Regulation of gene expression using single-chain, monomeric, ligand dependent polypeptide switchesSCRIPPS RESEARCH INST·Filed 2005·Granted Jun 22, 2010·0 cites·102 claims
- 2355US2024100180A1Tumor-specific claudin 18.2 antibody-drug conjugatesSOTIO BIOTECH A S·Filed 2021·Application pending·0 cites
- 2454US2007065408A1Modified polypeptides for targeting cell-entry of the adenoviruses of subtype bCYTOS BIOTECHNOLOGY AG·Filed 2004·Application pending·0 cites
- 2551US2024034783A1Tumor-specific claudin 18.2 antibodiesSOTIO BIOTECH A S·Filed 2020·Application pending·0 cites
- 2651US2013109845A1Fully human influenza m2 specific antibodiesINTERCELL AG·Filed 2012·Application pending·0 cites
- 2751US2023030674A1Humanized cldn18.2 antibodiesSOTIO BIOTECH A S·Filed 2020·Application pending·0 cites
- 2851US2021379194A1Binding protein-toxin conjugates comprising anthracyclines, and use thereof in immune-oncological applicationsNBE THERAPEUTICS AG·Filed 2019·Application pending·0 cites
- 2949US2010292089A1Selection of human monoclonal antibodies by mammalian cell displayCYTOS BIOTECHNOLOGY AG·Filed 2007·Application pending·0 cites
- 3048US2024158435A1Biocatalytical composition and use for generation of immunoligand-payload conjugatesINOFEA AG·Filed 2022·Application pending·0 cites
- 3147US2021139579A1Multispecific antibody product that binds to different ror1 epitopesNBE THERAPEUTICS AG·Filed 2018·Application pending·0 cites
- 3244US11845793B2Anti-ROR1 antibodiesNBE THERAPEUTICS AG·Filed 2016·Granted Dec 19, 2023·0 cites·8 claims
- 3336US2018028682A1Maytansine-drug conjugates of her-2 specific binding proteins generated by site specific sortase-enzyme mediated conjugationNBE THERAPEUTICS AG·Filed 2016·Application pending·0 cites
- 3436US2019112385A1Anti-mesothelin antibodiesNBE THERAPEUTICS AG·Filed 2016·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Roger Beerli files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →